Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROH-001 ophthalmic solution phase II clinical trial in patients with myopia
jRCT2031250015Phase 2Active, not recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in myopia comparing ROH-001 ophthalmic solution with Placebo ophthalmic solution (2 arms). Primary endpoint: Change in objective spherical equivalent. Started May 2025; status: active, not recruiting.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on jRCT2031250015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250015.